Clinical Trials & Medical Discoveries

Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models

by

OSAKA, Japan, May 29, 2023 /PRNewswire/ — RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting. Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and other autoimmune markers related to Pemphigus. Collaborators also reported that S/F-iTregs generated … Read more

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

by

Porustobart in combination of toripalimab showed promising anti-tumor activity Porustobart in combination of toripalimab showed acceptable safety profile in HCC Porustobart in combination of toripalimab showed favorable PK/PD signature CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, May 28, 2023 /PRNewswire/ — Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceutical company committed to the discovery, … Read more

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

by

TORONTO, May 27, 2023 /PRNewswire/ — Cora Therapeutics, a dynamic life sciences startup based in Toronto, proudly unveils the results of a clinical trial at the Canadian Association of Interventional Radiologists (CAIR) annual meeting in Quebec City. Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a … Read more

Menarini Group compartilha nova análise do estudo clínico EMERALD do ORSERDU® (Elacestrant) em câncer de mama metastático na ASCO 2023

by

ORSERDU (elacestrant) foi aprovado em janeiro de 2023 pelo FDA para câncer de mama avançado ou metastático positivo para receptor de estrogênio (ER), receptor 2 do fator de crescimento epidérmico humano (HER2) negativo com mutações ESR1 (ESR1-mut), que são encontradas em até 40% dos tumores  Em pacientes cujos tumores abrigam ESR1-mut, uma análise post-hoc anterior … Read more

Novavax’s Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

by

GAITHERSBURG, Md., May 26, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Nuvaxovid™ (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 … Read more

ProfoundBio Announces Further Advancement of Lead Programs

by

PRO1160 first patient dosed in the US China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023 /PRNewswire/ — ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics, announced that dosing in the Phase … Read more

SPRIM Global Investments Pte. Ltd. completes equity investment in UK specialist clinical trial site, VCTC Ltd.

by

SINGAPORE, May 26, 2023 /PRNewswire/ — SPRIM Global Investments (SPRIM), a leading health sciences investment firm, completed an equity investment in VCTC Limited, a UK-based specialist clinical trial site. SPRIM funding will enable VCTC to expedite growth through expansion of services and access to wider cross-portfolio opportunities. This investment is part of SPRIM’s strategy to … Read more

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference

by

SUZHOU, China, and ROCKVILLE, Md., May 25, 2023 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that 4 of its abstracts were selected for presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These studies … Read more

Daewoong Pharmaceutical veröffentlicht den molekularen Mechanismus von Bersiporocin als Antifibrotikum in der EMBO Molecular Medicine

by

Aufgeklärter molekularer Mechanismus hinter der Sicherheit und Wirksamkeit von Bersiporocin Bersiporocin befindet sich derzeit in einer klinischen Studie der Phase II zur Behandlung der idiopathischen Lungenfibrose SEOUL, Südkorea, 26. Mai 2023 /PRNewswire/ — Daewoong Pharmaceutical (CEO Lee Chang-jae und Jeon Sengho) gab am 25. Mai bekannt, dass der molekulare Mechanismus hinter der Sicherheit und Wirksamkeit … Read more

Huma named for its successful and innovative approach to clinical trials in new UK government review

by

Huma’s innovative approach to medical research cited in Lord James O’Shaughnessy’s review for clinical trials improvement in the UK The review is part of a new widespread policy approach to ignite the UK’s life sciences sector Innovating clinical trials using digital technologies such as Huma’s platforms can make them more accessible, more diverse, faster to … Read more